Skip to content

CNS Pharmaceuticals, Inc.

CNSP

CIK 0001729427

← back to feed
Revenue (TTM)
—
Q1 May 2026
Net Income (TTM)
−$14.83M
−6.7% YoY Q1 May 2026
EPS Diluted (TTM)
−$38.41
+92.3% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
—
Q1 May 2026
Net Margin
—
Q1 May 2026
Free Cash Flow (TTM)
−$15.92M
Q1 May 2026
Cash
$2.95M
Q1 May 2026
Total Debt
$449.87K
Q1 May 2026
Shares Outstanding
1.46M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings